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Abstract 
Background Depression has been associated with increased inflammatory proteins but 
changes in circulating immune cells are less well defined. 
Methods We used multi-parametric flow cytometry to count 14 subsets of peripheral 
blood cells in 206 cases of depression and 77 age- and sex-matched controls (total N = 
283). We used univariate and multivariate analyses to investigate the 
immunophenotypes associated with depression and depression severity.  
Results Depressed cases, compared to controls, had significantly increased immune 
cell counts, especially neutrophils, CD4+ T cells and monocytes, and increased 
inflammatory proteins (C-reactive protein, CRP, and interleukin-6, IL-6). Within-group 
analysis of cases demonstrated significant associations between the severity of 
depressive symptoms and increased myeloid and CD4+ T cell counts. Depressed cases 
were partitioned into two subgroups by forced binary clustering of cell counts: the 
inflamed depression subgroup (N=81 out of 206; 39%) had increased monocyte, CD4+ 
and neutrophil counts, increased CRP and IL-6, and was more depressed than the 
uninflamed majority of cases. Relaxing the presumption of a binary classification, data-
driven analysis identified four subgroups of depressed cases: two of which (N=38 and 
N=100; 67% collectively) were associated with increased inflammatory proteins and 
more severe depression, but differed in terms of myeloid and lymphoid cell counts. 
Results were robust to potentially confounding effects of age, sex, body mass index, 
recent infection, and tobacco use. 
Conclusions Peripheral immune cell counts were used to distinguish inflamed and 
uninflamed subgroups of depression and to indicate that there may be mechanistically 
distinct subgroups of inflamed depression.   
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Introduction 
There has been recent growth in the evidence for an association between depression 
and inflammation. Increased blood levels of inflammatory proteins (cytokines, like 
interleukin-6 (IL6), and C-reactive protein (CRP)) and increased expression of innate 
immune-related genes have been repeatedly reported in case-control studies of major 
depressive disorder (MDD) compared to non-depressed controls (1-6). There is 
experimental evidence that inflammation can cause depressive behaviours, both from 
animal studies showing that exposure to pro-inflammatory cytokines results in social 
withdrawal and anhedonia (7), and from human studies demonstrating that treatment 
(for hepatitis) with a pro-inflammatory cytokine (interferon) is followed by increased 
incidence of MDD (8). Convergently, meta-analytic reviews of clinical trial data have 
consistently demonstrated that anti-inflammatory drugs can significantly improve mood 
and fatigue symptoms, measured as secondary endpoints, in cases with major 
inflammatory disorder (9-11).  
 
Thus inflammatory mechanisms could be plausible targets for repurposing or de novo 
development of anti-inflammatory drugs for anti-depressant efficacy in cases with 
“inflamed depression”, i.e., clinical symptoms of depression associated with clinical or 
biomarker evidence of inflammation. Inflamed depression hypothetically includes cases 
of “co-morbid” depression associated with major medical inflammatory disease; as well 
as a subgroup of MDD cases with low-grade inflammation detectable by blood or brain 
biomarkers. The concept of inflamed depression as a subgroup of MDD implies that 
there is an un-inflamed subgroup of cases who are depressed without any evidence for 
inflammation. This is an important distinction to be able to make in the design of clinical 
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trials for immunergic anti-depressant drugs, which should be precisely focused on the 
cases most likely to have a positive benefit:risk response to treatment.  
 
Blood proteins – like cytokines and CRP – have been the focus of most immune 
biomarker research in psychiatry, to date; the potential utility of cellular immune markers 
has been relatively under-explored (12-18). Most case-control studies of leucocyte 
subsets have used small samples, limited immunophenotyping panels, and have 
generated somewhat inconsistent results. Depression has been reproducibly associated 
with leucocytosis, increased neutrophil to lymphocyte ratio, and increased ratio of CD4+ 
to CD8+ T cells (19-21). However, there are less consistent results concerning 
regulatory T cells, Th17 cells, natural killer (NK) cells, monocytes, and B cells (12-16, 
18, 22). Other psychiatric disorders, including schizophrenia, bipolar disorder and 
autism have also been associated with altered cell counts (23-25). Notably, most prior 
studies have measured the relative frequency of each immune cell subset in proportion 
to the superset of peripheral blood mononuclear cells (PBMCs). Such relative cell 
counts are difficult to interpret since a decrease in the relative proportion of any given 
subset may reflect either an absolute decrease in their number or an absolute increase 
in the number of another PBMC subset.  
 
We measured absolute numbers of 14 immune cell subsets from peripheral blood 
samples in 206 cases of depression and 77 healthy controls. We used multiple 
univariate and multivariate methods to identify cell counts that were significantly 
different between all cases and controls, and to explore the correlations between 
immune cells, inflammatory proteins and clinical variables. We tested the hypothesis 
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that a subgroup of depressed cases would have peripheral inflammation (26, 27) by a 
“top-down” analysis, dividing the cases into two subgroups based on their immune cell 
profiles, then testing for significant differences between them in terms of inflammatory 
proteins and clinical variables. We also used a more “bottom-up” or data-driven analysis 
to identify a theoretically unconstrained number of immune cell-stratified subgroups of 
cases and then tested for immunological and clinical differences between subgroups.  
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Materials and Methods 
Study design 
This was a case-control study of peripheral blood cell counts in depression cases and 
healthy controls.  
 
Depression cases were ascertained as those participants who screened positive for 
current or past depressive symptoms on the SCID screening questionnaire (28), 
completed the Hamilton Rating Scale for Depression (HAM-D), and screened negative 
for bipolar disorder or non-affective psychosis. 114 cases (55%) had moderate-severe 
depressive symptoms (HAM-D ≥ 17), of whom 61% were currently taking anti-
depressant medication; 50 cases (24%) had mild depressive symptoms (HAM-D 8-16) 
of whom 90% were currently medicated; and 42 cases (20%) had minimal depressive 
symptoms (HAM-D ≤ 7) of whom 100% were medicated. By design, this was a clinically 
heterogeneous sample inclusive of depressed cases across a spectrum of symptom 
severity and antidepressant medication exposure. 
 
Matched healthy controls were recruited from the general population by advertisement 
and defined as participants with no personal history of depression, no previous 
antidepressant treatment for any indication, no history of any major psychiatric disorder 
as defined by SCID screening questionnaire, and by current HAM-D total score <7.  
 
All participants satisfied inclusion criteria including age 25-50 years, and exclusion 
criteria including major medical disorder and immune-modulating drug treatment; see SI 
Methods for full list of eligibility criteria.  
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All study assessments were completed at one of five UK centers as part of the 
Biomarkers in Depression (BIODEP) study (4), which was approved by an independent 
research ethics committee (National Research Ethics Service East of England, 
Cambridge Central, UK; 15/EE/0092). All participants gave informed consent in writing 
and received £100 compensation.  
 
Assessments 
Participants completed the following clinical assessments and self-report 
questionnaires: Hamilton Depression Rating Scale (29); Beck Depression Inventory 
v2.0 (30); Chalder Fatigue Scale (31); Snaith-Hamilton Pleasure Scale (32); State-Trait 
Anxiety Inventory (33); Childhood Trauma Questionnaire (34); and Life Events 
Questionnaire (35). Height and weight were measured to calculate body mass index 
(mass / height2). For 269 of the 283 participants, the HAM-D, CRP, absolute cell counts 
and flow cytometry were measured in the same month; and, for all participants, these 
assessments were completed within 80 days.  
 
Fasting venous blood samples were taken between 8am and 10.30am for measurement 
of absolute blood cell counts (neutrophils, eosinophils, basophils, lymphocytes, 
monocytes, red cells and platelets); flow cytometry (CD4+ T cells, CD8+ T cells, B cells, 
classical monocytes, non-classical monocytes, intermediate monocytes, CD16hi NK 
cells, CD56hi NK cells and NKT cells); high-sensitivity C-reactive protein; lipid profile; 
and plasma interleukin-6 (IL6).  
 
Immuno-phenotyping 
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Flow cytometry was performed on fresh PBMCs using live-dead stain and antibodies 
against CD3, CD4, CD8, CD19, CD56, CD14 and CD16 (Table S1). Data were 
manually gated, blind to case/control status of each participant, according to the 
strategy in Figure S2. Flow cytometry counts were recorded as percentages relative to 
larger cell subsets, then multiplied by the relevant absolute cell counts to calculate 
absolute cell counts used in this study. For example, the absolute count of classical 
monocytes was calculated as the proportion of total monocytes that were classical 
monocytes (measured by cytometry) multiplied by the absolute number of monocytes 
(from the absolute cell count). This allowed calculation of absolute cell counts for CD4+ 
and CD8+ T cells; classical, intermediate and non-classical monocytes; CD16hi and 
CD56hi NK cells; NKT cells, and B cells (see Table S2 for all calculations).  
 
Statistical analysis 
All analyses were performed in [R] version 3.5.1 (R Core Team, 2018): see Data 
availability for code. P-values were corrected for multiple comparisons using the 
Benjamini-Hochberg procedure to control the false discovery rate (FDR). Group or 
subgroup effects on continuous variables were tested using Wilcoxon-Mann-Whitney or 
Kruskal Wallis tests, with FDR-corrected Conover non-parametric tests for post-hoc 
comparisons. (Sub)group effects on categorical variables were tested  by 2 tests with 
FDR-corrected 2 tests for post-hoc pairwise comparisons; see SI Methods for details.  
 
We used multivariate methods to deal with the high-dimensional, correlated data 
available on each participant. Principal components analysis (PCA) was used to identify 
the major dimensions of variation and co-variation over all 14 immune cell counts, using 
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data from all participants; partial least square discriminant analysis (PLS-DA) was used 
to identify the weighted function of immune cell counts most predictive of case/control 
status; partial least squares regression (PLS-R) was used to identify the weighted 
function of all 14 immune cell counts most strongly associated with multiple (four) 
clinical measures of depression severity within the cases, viz,  HAM-D, BDI, Chalder 
Fatigue and SHAPS scores. For both PLS discriminant analysis and regression, P-
values for the predictive ability of the models were estimated by permuting group labels 
or clinical score sets (5000 permutations). Significant weights were defined as those 
with an absolute bootstrapped Z-score >3 (24).  
 
We used Gaussian finite multivariate mixture modeling, and consensus clustering,  to 
identify subgroups of cases (and healthy controls) that shared an immune cell profile in 
common with each other and in contrast to the immune cells profile of cases in other 
subgroups (36, 37); see SI Methods for details.  
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Results 
Sample characteristics 
Quality-controlled absolute counts of 14 cell types were available on a sample of 283 
participants comprising 206 depressed cases (143 female, 66 male) and 77 healthy 
controls (52 female, 25 male). Case and control groups did not significantly differ in 
terms of mean age, sex, or current use of tobacco or cannabis. As expected, the cases 
were significantly more depressed, anxious and fatigued, and reported significantly 
more current stress, childhood trauma, alcohol use and unemployment, than controls 
(Table 1). By design, the cases were clinically heterogeneous, and enriched for 
moderate-severe depressive symptom scores despite current or past treatment with 
monoaminergic anti-depressant medication (Figure S1). 
 
Case-control differences in peripheral blood cell counts and inflammatory proteins  
We first estimated case-control differences in peripheral blood cell counts and 
inflammatory proteins using multiple univariate comparisons. Serum CRP (Mann-
Whitney U: P = 0.003, effect size = 0.18) and plasma IL-6 concentrations (P = 0.04, 
effect size = 0.14), as well as absolute counts of neutrophils (P = 0.01, effect size = 
0.15), intermediate monocytes (P = 0.02; effect size = 0.14) and CD4+ (helper) T cells 
(P = 0.003, effect size = 0.18), were significantly increased in the depressed group 
(Figure 1A, Table S3). When case-control comparisons were corrected for the 16 
biomarkers tested (FDR < 0.05), CRP and CD4+ T cells remained significantly different 
between the groups. 
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Correlational and principal components analysis of cellular, protein and clinical variables 
We estimated correlations between all immunological, clinical and demographic 
variables in the whole sample (N=283) (Figure 1B). Immune cell counts and 
inflammatory protein concentrations were positively correlated with each other, as were 
questionnaire measures of symptom severity and stress. The strongest pair-wise 
correlations between cell counts and clinical variables were between neutrophil count 
and HAM-D score (Spearman’s ρ = +0.27, FDR P = 0.00003), and neutrophil count and 
BDI score (ρ = +0.25, FDR P = 0.0002). The correlation matrix estimated from data on 
cases only (N=206) was very similar to the whole sample matrix (Figure S3). 
 
We used principal component analysis to summarise the correlated data on 14 blood 
cell counts in terms of the first 2 principal components, which together accounted for 
29% of the total variance-covariance. The first principal component (PC1; 19% total 
(co)variance) was a weighted average of all cell counts, most strongly weighted on 
myeloid cells (neutrophils, basophils and classical monocytes) and CD4+ T cells (Figure 
2A). The second principal component (PC2; 10% total (co)variance) was most strongly 
weighted on classical and non-classical monocytes and CD16hi NK cells (Figure S4A). 
Similar results were obtained when PCA was repeated for sex-specific subgroups of 
cases (Figure S4).  
 
PC1 scores were positively correlated with serum CRP (ρ = 0.26, FDR P = 0.00004), 
and IL-6 (ρ = 0.34, FDR P = 0.000004) concentrations. The depressed cases had 
higher mean PC1 scores than controls (Mann Whitney U: P = 0.006, standard effect 
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size = 0.16, Figure 2B) and PC1 scores were positively correlated with multiple 
measures of symptom severity including observer-rated depressive symptoms (HAM-D, 
ρ = 0.26, FDR P = 0.00004), self-reported depressive symptoms (BDI, ρ = 0.24, FDR P 
= 0.0002) and anhedonia (SHAPS, ρ = 0.23, FDR P = 0.0004), as well as BMI (ρ = 0.24, 
FDR P = 0.00004) (Figure 2B). A scatterplot of each participant’s scores on both PCs 
(Figure 2A) indicated that the majority of depressed cases had blood cell profiles 
overlapping those of healthy controls, but there was a subgroup of depressed cases 
with highly positive PC1 scores, indicating distinctively increased numbers of myeloid 
and CD4+ T cells. 
 
Discriminant analysis of immune cell counts most predictive of case/control status 
We used partial least squares (PLS) discriminant analysis (Figure 3A, S4E) to find the 
weighted function of the 14 immune cell counts that most accurately discriminated 
between cases and controls. This discriminant function accounted for a small but 
significant proportion (6.3%) of the variability in diagnostic status (P = 0.002, 
permutation test). Absolute cell counts for CD4+ T cells, neutrophils and eosinophils 
were significantly weighted on the discriminant function, indicating that a combination of 
these cell counts was most predictive of case/control status.  
 
Association of immune cell counts with severity of depression in cases 
We used PLS regression to test the hypothesis that a weighted function of immune cell 
counts predicted variability of depressive symptom severity among the cases. We found 
that a single PLS-R component accounted for a small (7.3%) but significant proportion 
of the variance in depressive symptom scores measured on multiple clinical 
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questionnaires (HAM-D, BDI, Chalder Fatigue and SHAPS) (P = 0.001, permutation 
test). The cell counts significantly weighted on the PLS-R component were neutrophils, 
NKT cells and B cells, indicating that a combination of these three cell counts was most 
strongly related to symptom severity, especially as self-reported by the BDI (Figure 3B).  
 
“Top-down” analysis of two subgroups of depressed cases 
To make a binary partition of depressed cases into two subgroups based only on their 
immune cell count data, we used Gaussian finite multivariate mixture modeling under 
the constraint that the number of distributions in the mixture must be two. This analysis 
identified one subgroup of N=81 cases (39%) that had increased absolute counts of 
several immune cells (monocytes, granulocytes, CD16hi NK cells, NKT cells, B cells, T 
cells and platelets) compared to a second subgroup of cases (N=125, 61%) (Figure 
4A,B).  
 
The subgroup of cases with increased immune cell counts also had significantly 
increased inflammatory protein concentrations (CRP, P = 0.03, standard effect size = 
0.16; and IL6, P = 0.02, standard effect size 0.19; Figure 4C, Table S4), compared to 
the second subgroup with decreased immune cell counts, and hence it was referred to 
as the inflamed depression subgroup. Cases of inflamed depression had significantly 
higher severity of observer-rated depressive symptoms (HAM-D, P = 0.0002, effect size 
= 0.26) and self-reported depressive symptoms (BDI, P = 0.01, effect size = 0.18), 
compared to the uninflamed depression cases. Inflamed vs uninflamed cases had twice 
the rate of unemployment (33% vs.17%, P = 0.008), were slightly older (median age 38 
years vs. 34 years, P = 0.01), and more likely to be smokers (19% vs. 7%, P = 0.01). 
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However, the two subgroups did not differ significantly on sex, study center, current 
antidepressant use, alcohol or cannabis use, reported recent infection or minor 
inflammatory disease, or BMI (Figure S5A,B, Table S4). 
 
Sensitivity analysis of immune cell binarization of un/inflamed depression 
To test the robustness of this key result – that binarization of all depression cases on 
cell counts identifies immunologically and clinically distinct subgroups of inflamed and 
uninflamed depression – we conducted two sensitivity analyses and a benchmarking 
study (detailed in Supplemental Material and summarized briefly here): (i) robustness to 
diagnostic eligibility criteria: we included only the subset of depression cases with a 
SCID diagnosis of major depressive disorder (MDD; N=139); (ii) robustness to potential 
confounds in case-control data: we used linear regression to mitigate the effects of age, 
sex, BMI, recent infection history and tobacco use before case-control analysis of 
residualised counts of the 14 immune cell subsets (Figures 4, S5, S6). In both these 
sensitivity analyses, we replicated identification of a subgroup of inflamed cases with 
more severe depressive symptoms. The first principal component of the residual cell 
counts was very similar to PC1 for the absolute counts (Figure 4E, S5A). Recapitulating 
the results for the absolute cell counts, PLS-R of residual cell counts identified a single 
component weighted on neutrophil and NKT cell counts as most predictive of 
depression severity (permutation test, P = 0.01). Binarization of depressed cases using 
residual immune cell counts again identified an inflamed subgroup with higher counts 
across all 14 cell types and increased HAM-D and BDI scores compared to an 
uninflamed subgroup (Figure 4E, 4F, S6). For benchmarking, the results of immune cell 
binarization of cases were compared to the results of binarization of controls (N=87). 
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Data-driven clustering identified a subgroup of controls (N=20) with very low cell counts 
and a subgroup with slightly higher cell counts (N=57) (Figure S8A). The marginally 
more inflamed subgroup was associated with higher BMI, higher IL-6, and male gender; 
but had significantly lower lymphoid and myeloid counts than the inflamed MDD cluster 
(Figure S8B).  
 
“Bottom-up” analysis of immune-cell stratified subgroups of cases 
We used Gaussian finite multivariate mixture modeling and consensus clustering, 
without prior constraint on the number of distributions in the mixture, to identify 4 
subgroups of cases (Figure 5, S7, Table S5), each characterized by a distinct profile of 
absolute immune cell counts (Figure 5B, S7A). One subgroup comprised 58 cases 
(28%) with low counts for all cells and low CRP and IL6 levels and was designated 
uninflamed (S0). Subgroups 2 and 3 had significantly increased inflammatory proteins, 
and significantly increased depressive symptom severity scores, compared to S0; but 
they also differed from each other in terms of their immune cell profiles. Subgroup 3 had 
a stronger myeloid bias compared to subgroup 2, with significantly higher numbers of 
classical monocytes, intermediate monocytes, non-classical monocytes and neutrophils 
(Figure S7A). Subgroup 2 had a lymphoid bias with significantly higher numbers of 
adaptive immune cells (CD4+ T cells, CD8+ T cells and B cells) compared to the 
uninflamed subgroup (Figure 5B, S7A). This four-way, bottom-up stratification of cases 
was not simply nested within the top-down binarization (Table S6). There were no 
significant differences between these 4 immune cell-stratified subgroups in terms of 
multiple, potentially confounding demographic and clinical factors (Figure S7B, Table 
S5).   
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Discussion 
 
Immune cell systems and depression 
We confirmed case-control mean differences in CRP and IL6, as well as increased 
absolute counts of neutrophils, intermediate monocytes, and CD4+ T cells in depressed 
cases, by the conventional approach of multiple univariate testing (Figure 1A) (1, 4, 5, 
19). We also observed that the immunological variables were correlated with each 
other, and with measures of depressive symptom severity, prompting further 
investigation with multivariate methods. The first principal component of the cellular data 
represented a weighted sum of all cell counts, especially myeloid and CD4+ T cells, and 
was positively correlated with both inflammatory protein concentrations and depressive 
symptom scores. Partial least squares (PLS) identified the weighted functions of 
immune cell counts, especially neutrophil cell counts, that optimally discriminated 
between cases or controls, or were most predictive of variation in depressive symptom 
severity.  
 
These results, in the context of the prior literature, tell us that peripheral blood cell 
counts are plausible as candidate biomarkers of “inflamed depression”, and the most 
informative cellular biomarkers are likely to summarise the status of a system of 
functionally or developmentally related cells, rather than a solitary “smoking gun”. 
Myeloid cells, especially neutrophils, were strongly implicated in these data. Absolute 
neutrophil numbers were increased in depressed cases, positively correlated with 
depressive symptom scores (Figure 1B), and strongly weighted on the PLS functions 
that optimally discriminated cases from controls or predicted symptom severity (Figure 
3). These findings are compatible with prior emphasis on the role of the innate immune 
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system in depression and, more specifically, with reports of case-control differences in 
total leucocyte count, neutrophil count, or neutrophil/lymphocyte ratio (19-21, 38). The 
hypercortisolemia observed in some depressed cases (39) may thus relate to the 
neutrophilia observed in these data and other studies (40, 41). Neutrophils can traffic to 
the brain and neutrophil depletion has been shown to mitigate the effects of 
inflammation on behavior in animal models (42). 
 
However, it would be simplistic at this stage to assert that myeloid cells are the only 
immune cells relevant to depression. For example, CD4+ helper T cells were correlated 
with myeloid cell counts, increased in depressed cases, and strongly weighted on the 
PLS discriminant function. Helper T cells are known to facilitate cytokine production and 
other inflammatory responses by myeloid cells (43); and myeloid antigen presenting 
cells are important for activating and polarizing CD4+ T cells towards a terminally 
differentiated state (44). In short, there are two-way interactions between myeloid and 
lymphoid cells that may underlie the observed pattern of depression-related change in 
multiple cell types. A role for adaptive as well as innate immunity in depression is also 
compatible with transcriptional results (6) that indicate coupled changes in peripheral 
whole blood expression of genes specialized for innate and adaptive immune functions.    
 
Immune cell stratified subgroups of depression 
These results also tell us that not all cases of depression are equally likely to be 
associated with abnormal immune cell counts, which is compatible with prior 
expectations of a subgroup of cases with “inflamed depression”. We tested this 
prediction more explicitly using mixture modeling to decompose the multivariate 
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distribution of immune cell counts in the depressed group into two or more component 
distributions or subgroups. Initially, we specified this analysis to identify two subgroups, 
which we found were indeed significantly different from each other immunologically and 
clinically. About 40% of depressed cases had increased immune cell counts, increased 
inflammatory proteins, and increased symptom severity scores, compared to the 
remaining 60% of uninflamed cases. These results are consistent with prior 
observations that approximately a third of MDD cases have CRP levels greater than the 
upper limit of the normal range (3 mg/L) and that depression is symptomatically more 
severe when associated with inflammation (4).  
 
However, there is no prior reason to assume that there should be only one subgroup of 
inflamed depression. When the multivariate mixture analysis was repeated, without 
constraining the algorithm to find a binary solution, we found 4 immune cell-stratified 
subgroups, of which two were associated with equivalently-increased inflammatory 
proteins and depressive symptom scores compared to the uninflamed subgroup. These 
two inflamed subgroups together accounted for about two thirds of cases, suggesting 
that the proportion of depression cases associated with inflammation may be 
underestimated by the conventional cut-off of CRP > 3 mg/L. Intriguingly, the existence 
of two inflamed subgroups, differentiated by their distinctively myeloid- vs lymphoid-
biased immune cell profiles, suggests that there may be more than one mechanistic 
pathway to the same syndrome of high depressive symptoms and increased 
inflammatory proteins. For example, some cases of inflamed depression may be caused 
primarily by proliferation or activation of myeloid cells, innately responding by pattern 
recognition receptors to acute stress or infection, whereas other cases may be driven by 
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T helper cells or B cells with a longer term memory of past exposure to stress, infection 
or other antecedent immune challenges. This concept of multiple species of inflamed 
depression, rather than a monolithic subgroup, could have important implications for the 
design of immunological interventions targeting more fundamentally causal 
mechanisms, rather than downstream biomarkers such as CRP or IL6.  
 
Methodological issues 
Case-control designs are vulnerable to the effects of uncontrolled confounding variables 
and there are many demographic, clinical, and lifestyle factors that could have effects 
on peripheral immune biomarkers. This sample of cases was designed to encompasses 
considerable clinical heterogeneity, which is useful for the within-group analysis, but is 
not epidemiologically representative. The sample is large (N=283; 206 cases), and the 
number of cell subsets counted is large (p=14), by comparison to prior immune cell 
studies of MDD; the order of magnitude difference between N and p is desirable for 
multivariate analysis. However, it will require an order of magnitude increase in sample 
size to fully explore and exploit the cellular resolution of contemporary immuno-
phenotyping for stratification of inflamed depression.   
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Figure legends 
 
Figure 1: Peripheral immunophenotypes in MDD and control participants 
(A) Comparison of 14 absolute cell counts, high sensitivity CRP and plasma IL-6 in 
major depressive disorder (MDD, n=206) and matched controls (n=77). Boxplots show 
median and interquartile range, with the outer violin shape showing the full distribution 
of data. Color indicates statistical significance by Mann Whitney U test (purple P < 0.05; 
red FDR P < 0.05). FDR p-values are corrected for 16 multiple comparisons. See Table 
S3 for underlying data and effects sizes. 
(B) Spearman correlations between immunological, clinical and demographic variables. 
Only those correlations significant at FDR P < 0.05 are shown. FDR p-values are 
corrected for 325 multiple comparisons. Color indicates the correlation coefficient 
(Spearman’s ρ); dark blue outlines group together similar variables. 
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Figure 2: Principal components analysis of cellular immunophenotypes 
(A) Principal components analysis (PCA) for the 14 absolute cell counts across all 
participants (n=283). On the left panel, each point (MDD in blue; controls in grey) 
represents one participant’s scores on the first two principal components (PC1 and 
PC2). Red arrows show the loadings of each cell count on the first two principal 
components. Ellipses show the 95% confidence ellipse for each group. Right hand 
panel shows the PCA eigenvector for PC1. See Figure S4 for PC2 and PCA excluding 
cases with minor inflammatory conditions, and for each sex separately. 
(B) Spearman correlations between the first principal component of the cellular 
immunophenotype (PC1), clinical features, demographic features, and peripheral 
proteins (n=283 participants). Only correlations significant at FDR P < 0.05 are shown. 
FDR p-values are corrected for 33 multiple comparisons. Color indicates the correlation 
coefficient (Spearman’s ρ). The right-hand side boxplot shows the PC1 scores for MDD 
cases and controls (Mann-Whitney test, estimate=0.54, effect size=0.16, P = 0.006). 
Boxplots show median and interquartile range, outer violin shape shows the full 
distribution of data.  
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Figure 3: Cellular predictors of MDD status and symptoms severity 
(A) Partial least squares discriminant analysis (PLS-DA) for the predictors of case-
control status. Response variable is major depressive disorder (MDD)/control status 
(purple point), predictor variables are the 14 absolute cell counts from Figure 1A (green 
points). Analysis includes all participants (n=283). A single component PLS model 
(Component 1) is significantly predictive of MDD status by permutation testing (P = 
0.002). Of the 14 cell types, only those with significant weights in the model are labelled: 
neutrophils, eosinophils and CD4+ T cells (bootstrapped Z-score >3, see Methods). See 
also Figure S4E. 
(B) Partial least squares regression (PLS-R) for the predictors of depressive symptom 
severity within the MDD group. Response variable is the matrix of symptoms scores 
(shown in purple), predictor variables are the 14 absolute cell counts (green points). A 
single component PLS model (Component 1) is significantly predictive of MDD severity 
by permutation testing (P = 0.001). Of the 14 predictor cell types, only those with 
significant weights in the model are labelled: neutrophils, NKT cells and B cells 
(bootstrapped Z-score >3, see Methods). Analysis includes MDD cases only (n=199 
with full clinical scores available). SHAPS = Snaith-Hamilton Pleasure Scale. HAM = 
Hamilton Depression Rating Scale. 
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Figure 4: Theoretically driven immune cell stratification into inflamed and 
uninflamed MDD subgroups  
(A) Gaussian finite mixture modelling of the cellular phenotypes for MDD cases (n=206). 
Forced two-way mixture modelling identified two clustered immunophenotypes, 
uninflamed depression (UD, n=125 cases, grey) and inflamed depression (ID, n=81, 
red). Plot shows the PCA scores for each case on cellular PC1 and PC2 (Figure S5A), 
with cluster membership indicated by color.  
(B, C, D) Comparisons between the two clusters. Boxplots show median and 
interquartile range for each cluster, with the outer violin shape showing the full 
distribution of data. Effects of cluster were tested by Mann-Whitney U or (for 
unemployment) 2, *P<0.05, **P<0.01, ***P<0.01. (B) Absolute cell counts (inputs to 
clustering). (C) Peripheral blood markers: C-reactive protein (CRP), interleukin-6 (IL-6) 
and triglycerides (not used as inputs to clustering). (D) Clinical phenotype of participants 
in each cluster. Bar annotations indicate participant numbers. See Table S4 and Figure 
S5 for statistics, further clinical and demographic measures and item-level scores 
corresponding to MDD ‘typicality’.  
(E) Sensitivity analysis: principal components analysis (PCA) of the 14 residual cell 
counts after linear regression of body mass index (BMI), age, sex, current tobacco use 
and recent infection on each cell count (MDD cases only, N=206). Left-hand panel 
shows the eigenvector for the first principal component of the residual cell counts (PC1). 
Right hand panel shows the results of forced two-way clustering of the residual cell 
counts, which identified two immune cell-stratified subgroups of cases: uninflamed 
depression (N=104, grey) and inflamed depression (N=102, red), overlaid on a 
scatterplot of PCA scores.  
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(F) Depression rating scores for inflamed and uninflamed cases identified by 
binarization of residual immune cell counts. Inflamed vs uninflamed subgroup 
differences were tested by Mann-Whitney U, *P<0.05, **P<0.01. HAM-D = Hamilton 
Depression Rating Scale (practitioner-administered), BDI = Beck Depression Inventory 
(self-report). 
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Figure 5: Data-driven immune cell stratified MDD subgroups 
(A) Data-driven Gaussian finite mixture modelling of the cellular phenotypes for MDD 
cases (n=206) identified four discrete clusters (immunophenotypes). Plot shows the 
PCA scores for each participant on cellular PC1 and PC2, with cluster indicated by 
color. The arbitrary cluster numbers and colors are used consistently throughout this 
figure to designate each cluster (cluster 0, grey, n=58 cases; cluster 1, orange, n=10; 
cluster 2, blue, n=100; cluster 3, red, n=38). 
(B) A radar plot shows the characteristic immune cell profile of each cluster of cases.  
Points represents the median value of the 14 absolute cell counts for each of the four 
clusters, rescaled onto a 0 to 1 range (with higher values on the outside of the plot) to 
highlight relative differences between clusters. Cluster differences are significant for all 
counts shown (Kruskal-Wallis P<0.05); red blood cell and CD56hi NK cell counts did not 
differ between the clusters and are not shown. See Figure S7A for underlying data and 
statistics. 
(C, D) Inflammatory proteins, clinical and demographic data for each immune cell-
stratified subgroup of cases. Cases in subgroup 3 (inflamed, myeloid-biased) had 
significantly increased observer-rated depressive symptoms (HAM-D, FDR P = 0.004), 
self-reported depressive symptoms (BDI, FDR P = 0.006), and anhedonia (SHAPS, 
FDR P = 0.006), compared to the uninflamed subgroup. Cases in subgroup 2 (inflamed, 
lymphoid-biased) likewise had significantly increased self-reported depressive 
symptoms (BDI; FDR P = 0.003), anhedonia (SHAPS; FDR P = 0.004), and fatigue 
ratings (CFS; FDR P = 0.02), compared to the uninflamed subgroup. Boxplots show the 
median and inter-quartile range of the relevant variable for each cluster, violin outline 
shows the full distribution of data. The effect of cluster on each continuous feature is 
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tested by Kruskal-Wallis testing. Where P < 0.05 for the overall Kruskal-Wallis test, we 
performed post-hoc Conover tests to identify which pairs of clusters differ for that 
feature – for these variables, each cluster was compared to every other cluster. For 
unemployment, the bar chart indicates the percentage of participants in each cluster 
and bar annotations indicate participant numbers. Clusters were compared by 2 
testing, with post-hoc 2 tests to compare pairs of clusters. All p-values shown are 
corrected for the 6 pairwise cluster-cluster comparisons performed: FDR P *<0.05, 
**<0.01, and ***<0.001. Pairwise comparisons which were non-significant following FDR 
correction are not shown. For further statistics, demographics and item-level scores 
corresponding to MDD ‘typicality’ see Figures S7, Table S5. HAM-D = Hamilton 
Depression Rating Scale (practitioner-administered), BDI = Beck Depression Inventory 
(self-report), SHAPS = Snaith-Hamilton Pleasure Scale. 
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Table 1: Demographic and clinical characteristics of the study population (see caption over) 
 
 
 
Participant characteristics Control 
(median, 
IQR) 
MDD 
(median, 
IQR) 
P-value 
(MWU) 
/√() 
Effect 
size 
n (missing 
data) 
Number of participants N = 77 N = 206 -    
Age 32.5 
(28.3, 39.1) 
35.3 
(28.7, 42.9) 
0.09 0.10 0 
BMI 23.5 
(21.3, 27.6) 
26.6 
(23.0, 31.2) 
***0.0008 0.20 8 
Hamilton depression rating 0 
(0.0, 1.0) 
17 
(14.0, 20.0) 
***2E-53 0.74 0 
Beck depression inventory  1 
(0.0, 3.0) 
24 
(15.0, 31.2) 
***8E-43 0.70 6 
Chalder fatigue score 11 
(8.0, 11.0) 
19 
(14.0, 23.5) 
***4E-33 0.64 3 
Snaith-Hamilton Pleasure 
Scale  
0 
(0, 0) 
4 
(1, 7) 
***2E-24 0.58 4 
STAI (state subscale) 25 
(22.0, 29.0) 
50 
(38.5, 57.5) 
***2E-39 0.68 3 
STAI (trait subscale) 27 
(24.0, 32.0) 
60 
(52.0, 68.0) 
***1E-48 0.73 3 
Childhood trauma score 35.0 
(33.0, 38.5) 
49.5 
(40.0, 62.0) 
***3E-19 0.51 6 
Recent stressors (z-score) -0.9 
(-0.9, -0.3) 
-0.2 
(-0.4, 0.5) 
***1E-10 0.37 4 
Number of previous 
ineffective antidepressant 
treatments (<75% response) 
- 1.0 
(1.0, 3.0) 
- - 7 
 Control 
(percent) 
MDD 
(percent) 
P-value 
2
 
n (missing 
data) 
Female sex 68% 69% 0.8 0.09 0 
Unemployed (including for 
medical reasons) 
0% 23% ***0.0005 21.4 3 
Current tobacco use 11% 12% 0.8 0.09 4 
Current alcohol use 33% 48% *0.03 4.81 5 
Current cannabis use 3% 6% 0.3 1.57 5 
Current antidepressant use - 75% -  5 
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Table 1: Demographic and clinical characteristics of the study population 
P-values for comparison of control vs. MDD by Mann-Whitney (MWU, continuous 
variables) or 2 testing (categorical variables): *p<0.05, **p<0.01, and ***p<0.001. MDD, 
major depressive disorder; IQR, interquartile range; BMI, body mass index; STAI, Stait-
Trait Anxiety Inventory. Number of missing data values for each variable are also shown 
(total n=283 participants). 
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